Ascendis Pharmac
ASND249.1401.15% ( -2.910 )
Ascendis Pharmac (ASND)
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United S...
- Open
- 250.000
- High
- 253.065
- Low
- 246.010
- Prev. Close
- 252.050
- Volume
- 98.36K
- Turnover
- 24.43M
- Avg Price
- 248.425
- Bid/Ask Ratio
- --
- Amplitude
- 2.80%
- 52wk High
- 282.150
- Volume Ratio
- 0.57
- Turnover Ratio
- 0.16%
Ascendis Pharmac Analyst Rating
View MoreForecast & Rating
Jul 23, 2026Price forecast
$305.5322.63%
Forecast & RatingStrong buy
18analysts
- Strong buy77.78%
- Buy22.22%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · Jul 24 at 02:26 AM
Bank of New York Mellon Corp Reduces Stock Position in Ascendis Pharma A/S $ASND
- Market Beat · Jul 22 at 03:09 AM
Barometer Capital Management Inc. Reduces Holdings in Ascendis Pharma A/S $ASND
- Simplywall · Jul 21 at 04:04 AM
Ascendis Pharma (ASND) Could Be 14% Below Fair Value As Growth Hopes Hold
- Market Beat · Jul 17 at 04:37 AM
Marks Group Wealth Management Inc Purchases New Shares in Ascendis Pharma A/S $ASND
- Market Beat · Jul 13 at 03:44 AM
Ascendis Pharma A/S (NASDAQ:ASND) Given Consensus Rating of "Buy" by Analysts
- Simplywall · Jul 12 at 12:23 AM
Ascendis Pharma (ASND) Says 104 Week TransCon CNP Data Still Looks Strong
